Meeting
2021 ASCO Annual Meeting
A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
Authors
Nashat Y. Gabrail
Gabrail Cancer Center Research LLC, Canton, OH
Nashat Y. Gabrail , Erika P. Hamilton , Anthony D. Elias , Mothaffar F. Rimawi , Chao Li , Maria Margarita Corvez , Wei Li , Ying Feng , Jiao Wei , Stephanie Greene , John Patterson , Qingping Zeng , Ai-Min Hui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT03950570
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3080)
DOI
10.1200/JCO.2021.39.15_suppl.3080
Abstract #
3080
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
First Author: Mothaffar F. Rimawi
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
First Author: Sarina A. Piha-Paul